AstraZeneca plc (AZN) Expected to Announce Quarterly Sales of $5.76 Billion
Equities analysts expect AstraZeneca plc (NYSE:AZN) to post sales of $5.76 billion for the current quarter, Zacks reports. Three analysts have provided estimates for AstraZeneca’s earnings. The lowest sales estimate is $5.37 billion and the highest is $6.12 billion. AstraZeneca reported sales of $5.59 billion in the same quarter last year, which would suggest a positive year over year growth rate of 3%. The business is expected to report its next earnings results on Thursday, February 1st.
According to Zacks, analysts expect that AstraZeneca will report full-year sales of $5.76 billion for the current financial year, with estimates ranging from $20.03 billion to $22.48 billion. For the next year, analysts anticipate that the business will report sales of $22.07 billion per share, with estimates ranging from $20.47 billion to $23.93 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow AstraZeneca.
AstraZeneca (NYSE:AZN) last released its earnings results on Thursday, November 9th. The company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.55. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The company had revenue of $6.23 billion for the quarter, compared to the consensus estimate of $6 billion. During the same period in the prior year, the company posted $1.32 EPS. The company’s revenue was up 9.4% compared to the same quarter last year.
Several hedge funds have recently made changes to their positions in the company. Garrison Financial Corp increased its stake in shares of AstraZeneca by 0.5% in the 2nd quarter. Garrison Financial Corp now owns 18,058 shares of the company’s stock valued at $616,000 after acquiring an additional 86 shares during the last quarter. Dorsey & Whitney Trust CO LLC increased its stake in AstraZeneca by 0.7% during the 2nd quarter. Dorsey & Whitney Trust CO LLC now owns 13,315 shares of the company’s stock worth $454,000 after purchasing an additional 94 shares in the last quarter. Financial Counselors Inc. increased its stake in AstraZeneca by 2.7% during the 2nd quarter. Financial Counselors Inc. now owns 6,871 shares of the company’s stock worth $234,000 after purchasing an additional 182 shares in the last quarter. FTB Advisors Inc. increased its stake in AstraZeneca by 3.2% during the 2nd quarter. FTB Advisors Inc. now owns 6,471 shares of the company’s stock worth $197,000 after purchasing an additional 200 shares in the last quarter. Finally, Pinnacle Financial Partners Inc. increased its stake in AstraZeneca by 2.5% during the 2nd quarter. Pinnacle Financial Partners Inc. now owns 9,233 shares of the company’s stock worth $314,000 after purchasing an additional 229 shares in the last quarter. 14.75% of the stock is owned by institutional investors.
AstraZeneca (NYSE AZN) opened at $32.74 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.72 and a debt-to-equity ratio of 1.09. AstraZeneca has a 52-week low of $26.51 and a 52-week high of $35.60. The stock has a market cap of $82,894.28, a PE ratio of 7.81, a price-to-earnings-growth ratio of 2.98 and a beta of 0.72.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/10/astrazeneca-plc-azn-expected-to-announce-quarterly-sales-of-5-76-billion-2.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.